Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.

Harada, Ken-Ichi; Miyake, Hideaki; Furukawa, Junya; Fujimoto, Naohiro; Fujisawa, Masato

Harada, Ken-Ichi; Miyake, Hideaki; Furukawa, Junya; Fujimoto, Naohiro; Fujisawa, Masato.

Afiliación

Harada KI; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyake H; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Furukawa J; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Fujimoto N; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Fujisawa M; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Int J Urol ; 29(8): 816-822, 2022 08.

Article en En | MEDLINE | ID: mdl-35636920

Asunto(s)

Antineoplásicos; Carcinoma de Células Renales; Neoplasias Renales; Antineoplásicos/uso terapéutico; Carcinoma de Células Renales/patología; Humanos; Inmunoterapia; Neoplasias Renales/patología; Pronóstico

Palabras clave

advanced renal cell carcinoma; combination therapy; first-line treatment; immuno-oncology drugs; prognostic outcome

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Int J Urol Asunto de la revista: UROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google